- Home
- DOMH vs CTOR Comparison
DOMH vs CTOR Comparison
Compare DOMH & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- CTOR
- Stock Information
- Founded
- DOMH 1967
- CTOR 2021
- Country
- DOMH United States
- CTOR United States
- Employees
- DOMH N/A
- CTOR N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- DOMH Health Care
- CTOR
- Exchange
- DOMH Nasdaq
- CTOR NYSE
- Market Cap
- DOMH 74.9M
- CTOR 89.9M
- IPO Year
- DOMH N/A
- CTOR N/A
- Fundamental
- Price
- DOMH $8.20
- CTOR $1.17
- Analyst Decision
- DOMH
- CTOR Strong Buy
- Analyst Count
- DOMH 0
- CTOR 2
- Target Price
- DOMH N/A
- CTOR $4.50
- AVG Volume (30 Days)
- DOMH 4.4M
- CTOR 61.5K
- Earning Date
- DOMH 03-31-2025
- CTOR 02-14-2025
- Dividend Yield
- DOMH N/A
- CTOR N/A
- EPS Growth
- DOMH N/A
- CTOR N/A
- EPS
- DOMH N/A
- CTOR N/A
- Revenue
- DOMH $12,589,000.00
- CTOR N/A
- Revenue This Year
- DOMH N/A
- CTOR N/A
- Revenue Next Year
- DOMH N/A
- CTOR N/A
- P/E Ratio
- DOMH N/A
- CTOR N/A
- Revenue Growth
- DOMH 1117.50
- CTOR N/A
- 52 Week Low
- DOMH $0.83
- CTOR $0.85
- 52 Week High
- DOMH $13.58
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- DOMH 58.54
- CTOR N/A
- Support Level
- DOMH $8.25
- CTOR N/A
- Resistance Level
- DOMH $12.00
- CTOR N/A
- Average True Range (ATR)
- DOMH 2.15
- CTOR 0.00
- MACD
- DOMH 0.40
- CTOR 0.00
- Stochastic Oscillator
- DOMH 51.22
- CTOR 0.00
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.